A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Phase 1a is an open-label, multi-dose, single-arm, dose-escalation study to define the toxicity profile, pharmacokinetics, and antitumor activity of SGN-33 in patients with myelodysplastic syndrome (MDS), acute myelogenous leukemia(AML), and CD33+ myeloproliferative diseases. Phase 1b includes patients with AML or MDS treated at the highest tolerated dose from phase 1a.
Acute Myeloid Leukemia|Myelodysplastic Syndrome|Myeloproliferative Disorders|Chronic Myelomonocytic Leukemia
DRUG: lintuzumab
The incidence of adverse events and lab abnormalities., 13 months|Pharmacokinetic (PK) profile and immunogenicity (Human Anti-Human Antibody; HAHA)., 13 months|Antitumor activity., 13 months
Phase 1a is an open-label, multi-dose, single-arm, dose-escalation study to define the toxicity profile, pharmacokinetics, and antitumor activity of SGN-33 in patients with myelodysplastic syndrome (MDS), acute myelogenous leukemia(AML), and CD33+ myeloproliferative diseases. Phase 1b includes patients with AML or MDS treated at the highest tolerated dose from phase 1a.